Related Experiment Video
Updated: Apr 17, 2026
Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
Published on: January 22, 2014
Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer's disease
Yan Zhu1, Chengshan Li1, Aichen Sun1
1Department of ICU, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China.
Abstract:
The aim of the present study was to investigate the potential clinical application of the genetic marker microRNA (miRNA)-210 in the cerebrospinal fluid (CSF) and serum of patients with Alzheimer's disease (AD). The enrolled patients were divided into the mild cognitive impairment (MCI) and AD groups. Healthy individuals were used as the controls. The mRNA and protein expression of vascular endothelial growth factor (VEGF) in the CSF and serum samples was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively. The expression of miRNA-210 in the CSF and serum was detected by RT-qPCR. The results revealed that the mRNA and protein expression levels of VEGF in the CSF and serum were decreased in the MCI and AD groups compared with those in the control group. The greater the severity of the dementia, the lower the mRNA and protein expression of VEGF. Similar to the trend observed for VEGF, the miRNA-210 expression in the CSF and serum decreased as the severity of the AD increased. miRNA-210 is thus not only indicative of AD pathogenesis, but may also provide novel insights into the prevention and treatment of the disease.
Insights
This study found that microRNA-210 (miRNA-210) levels in cerebrospinal fluid and serum decrease with Alzheimer's disease (AD) severity. Lower levels of vascular endothelial growth factor (VEGF) were also observed in patients with AD.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Biomarkers for early diagnosis and monitoring of AD are crucial.
- MicroRNAs (miRNAs) are emerging as potential diagnostic and prognostic indicators in neurological diseases.
Purpose of the Study:
- To investigate the clinical utility of microRNA-210 (miRNA-210) as a biomarker in cerebrospinal fluid (CSF) and serum of Alzheimer's disease (AD) patients.
- To assess the relationship between miRNA-210 expression and disease severity.
- To explore the correlation between miRNA-210 and vascular endothelial growth factor (VEGF) in AD.
Main Methods:
- Recruitment of patients with mild cognitive impairment (MCI) and AD, along with healthy controls.
- Quantification of vascular endothelial growth factor (VEGF) mRNA and protein expression using RT-qPCR and Western blot in CSF and serum.
- Detection of miRNA-210 expression in CSF and serum via RT-qPCR.
Main Results:
- Vascular endothelial growth factor (VEGF) mRNA and protein levels were significantly reduced in both CSF and serum of MCI and AD patients compared to controls.
- A negative correlation was observed between VEGF expression levels and the severity of dementia.
- MicroRNA-210 (miRNA-210) expression in CSF and serum showed a similar decreasing trend with increasing AD severity.
Conclusions:
- MicroRNA-210 (miRNA-210) levels in CSF and serum are indicative of Alzheimer's disease (AD) pathogenesis.
- Decreased expression of miRNA-210 correlates with AD progression, suggesting its potential as a prognostic biomarker.
- The findings suggest that miRNA-210 may offer novel insights for the prevention and treatment strategies for AD.
